Global Medical Device Vigilance Management: Navigating Regulatory Differences to Ensure Compliance and Patient Safety

Importance

Medical device vigilance is not optional, failure to meet vigilance requirements can lead to:

• Regulatory observations
• Warning letters or enforcement actions
• Loss of market trust
• Increased audits scrutiny

By placing multiple regions side by side, the infographic makes it immediately clear that success in vigilance depends on speed, clarity, and regional expertise.

United Kingdom: MHRA’s MORE System

Post-Brexit, the UK has developed its own vigilance system under the Medicines and Healthcare products Regulatory Agency (MHRA). Reporting is carried out through the MORE (Manufacturer’s On-line Reporting Environment) system. Reporting timeline include:

• Serious public health threats need to be reported within 2 calendar days
• Deaths or serious deterioration of health need to be reported within 10 calendar days
• Other serious incidents must be reported within 15 calendar days

These timelines are similar to EU requirements but are tailored to the UK’s independent regulatory framework.

Reporting System

• Reports are submitted electronically via the MORE system.
• Manufacturers must also notify their UK Approved Body of incidents, depending on contractual arrangements.
• Recent updates (2025) introduced UK specific fields, enhanced traceability, and stricter requirements for Unique Device Identifiers (UDI) and IMDRF coding.
• MHRA may request Periodic Summary Reports (PSRs) to monitor recurring issues.

European Union: EUDAMED Oversight of Medical Device Vigilance

In the European Union, medical device vigilance is governed by the Medical Device Regulation (MDR, EU 2017/745) and the In Vitro Diagnostic Regulation (IVDR, EU 2017/746). Oversight is shared between National Competent Authorities (NCAs) and the European Commission, with reporting centralized through the EUDAMED vigilance module. This framework ensures that adverse events are captured consistently across all Member States, supporting transparency and patient safety.

Reporting Timelines

• Serious public health threat: Must be reported within 2 calendar days.
• Death or serious deterioration of health: Must be reported within 10 calendar days.
• Other serious incidents: Must be reported within 15 calendar days.

These timelines are harmonized across the EU, ensuring consistency and comparability between Member States.

Reporting System

• Reports are submitted electronically via the EUDAMED vigilance module, which provides a single EU wide platform for incident reporting.
• Manufacturers, authorized representatives, and importers are responsible for vigilance reporting.
• NCAs review reports and coordinate corrective actions, while the European Commission monitors overall system performance.
• Trend reporting and Periodic Summary Reports (PSURs) are permitted, allowing manufacturers to demonstrate proactive monitoring of recurring issues.

United States: FDA Oversight of Medical Device Vigilance

In the United States, medical device vigilance is overseen by the Food and Drug Administration (FDA) under the Medical Device Reporting (MDR) regulation (21 CFR Part 803). This framework ensures that adverse events and product problems are reported promptly, enabling the FDA to monitor device performance and protect public health.

Reporting Timelines

• Manufacturers and Importers:
  • Deaths, serious injuries, or malfunctions → Must be reported within 30 calendar days.
  • 5 day reports → Required if FDA requests them or if the manufacturer becomes aware of an event that necessitates immediate remedial action.
• User Facilities (e.g., hospitals, nursing homes):
  • Deaths → Must be reported to both the FDA and the manufacturer within 10 working days.
  • Serious injuries → Must be reported to the manufacturer within 10 working days (or to the FDA if the manufacturer is unknown).

Reporting System

• Reports are submitted electronically through the FDA’s Electronic Medical Device Reporting (eMDR) system.
• Manufacturers must maintain robust internal SOPs to ensure timely escalation and accurate classification of events.
• FDA requires unique device identifiers (UDI) to be included in reports, strengthening traceability.

Japan: PMDA and MHLW Oversight

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) is responsible for vigilance. Reporting deadlines are :

• For death or serious injury must be reported within 15 calendar days
• For other adverse events must be reported within 30 calendar days

Reports are submitted directly to PMDA, and manufacturers must ensure their SOPs reflect calendar-day calculations, not working days. This distinction is critical for compliance. Japan emphasizes documentation and consistency, requiring manufacturers to classify severity accurately and maintain robust internal reporting systems.

China : National Medical Products Administration (NMPA)

China’s National Medical Products Administration (NMPA) has strengthened vigilance requirements through regulatory reforms. The Regulation on the Supervision and Administration of Medical Devices (revised in 2025) mandates:

• For serious incidents death or serious public health threat must be reported within 10 calendar days
• For other reportable adverse events must be reported within 15–30 calendar days, depending on severity

China’s vigilance system is changing, with increasing emphasis on transparency and alignment with international standards. Manufacturers must also consider language and local requirements, as submissions must be in Chinese.

Canada: Medical Devices Regulations (SOR-98-282)

Canada’s vigilance system is governed by the Medical Devices Regulations (SOR-98-282) and control by Health Canada. Timelines are as followed:

• For death or serious deterioration of health it must be reported within 10 calendar days.
• Potential for death or serious deterioration of health it must be reported within 30 calendar days.

This distinction between actual and potential harm reflects Canada’s pragmatic approach. Reports are submitted via the Medical Device Problem Reporting system, and manufacturers must align vigilance timelines with their periodic safety update reports (PSURs) to demonstrate consistency. Canada’s system is notable for its clarity and emphasis on proportionality.

Australia: TGA Oversight of Medical Device Vigilance

In Australia, medical device vigilance is overseen by the Therapeutic Goods Administration (TGA). The vigilance framework is part of the broader post market monitoring system, ensuring that adverse events and safety concerns are promptly reported and addressed to protect patients and maintain regulatory trust.

Reporting Timelines

• Death or serious injury → Must be reported within 10 calendar days.
• Other adverse events → Must be reported within 30 calendar days.

These timelines align with international norms but emphasize proportionality: urgent threats require rapid reporting, while less severe incidents allow for a longer window.

Reporting System

• Reports are submitted through the Medical Device Incident Reporting (MDIR) system, which is integrated into the TGA’s broader Incident Reporting and Investigation Scheme (IRIS).
• Since March 2026, mandatory reporting obligations have expanded to include healthcare facilities, not just sponsors. This change strengthens transparency and ensures that incidents are captured directly from clinical environments.
• Sponsors remain responsible for ensuring that vigilance obligations are met, including coordination with healthcare providers and subcontractors.

Brazil: ANVISA Oversight of Medical Device Vigilance

In Brazil, medical device vigilance is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA) through its Technovigilance system (Sistema Nacional de Vigilância Sanitária – SNVS). The framework is designed to ensure rapid detection, reporting, and corrective action for adverse events, protecting patients and strengthening regulatory accountability.

Reporting Timelines

• Death or serious public health threat: Must be reported within 72 hours if the incident occurs in Brazil, or within 10 calendar days if outside Brazil.
• Serious adverse events: Must be reported within 10 calendar days.
• Malfunctions with potential to cause harm: Must be reported within 30 calendar days.

These timelines reflect Brazil’s emphasis on speed and proportionality, ensuring urgent threats are escalated immediately while allowing more time for less severe events.

Reporting System

• Reports are submitted through ANVISA’s Technovigilance portal, which centralizes incident reporting and corrective actions.
• The Brazil Registration Holder (BRH) is legally responsible for vigilance reporting, even if the manufacturer is located abroad.
• Reports must be submitted in Portuguese, and corrective actions (such as recalls or field safety notices) must be communicated to both ANVISA and affected users.

New Zealand: Medsafe Oversight of Medical Device Vigilance

In New Zealand, medical device vigilance is overseen by Medsafe, the Medicines and Medical Devices Safety Authority under the Ministry of Health. Unlike some jurisdictions with rigid statutory timelines, New Zealand’s vigilance framework emphasizes prompt notification and proactive monitoring rather than fixed deadlines.

Reporting Timelines

• Serious adverse events (death or serious injury): Must be reported immediately once identified.
• Other adverse events: Must be reported as soon as practicable, with urgency determined by severity and potential risk.

This flexible approach reflects New Zealand’s reliance on sponsor accountability and clinical judgment, rather than prescriptive calendar day rules.

Reporting System

• Reports are submitted through the WAND (Web Assisted Notification of Devices) database, which serves as the national registry for medical devices.
• Sponsors and importers are responsible for ensuring vigilance obligations are met, including coordination with healthcare providers.
• Healthcare professionals and facilities are encouraged to report incidents directly to Medsafe, but the primary responsibility rests with sponsors.

Comparison table summarizing the vigilance reporting deadlines for Japan, China, Canada, the UK. USA, Australia, New Zealand, Brazil and EU.

Medical Device Vigilance Reporting Deadlines

Final Thought

Medical device vigilance management has evolved into a critical regulatory function, not just an administrative requirement. It is important for regulatory compliance and patient safety. Comparing vigilance systems in Japan, China, Canada,the UK, USA, Brazil, Canada, Australia, New Zealand and EU reveal shared priorities which is patient safety, transparency, and accountability although they have procedural differences.

For global manufacturers, these differences make it essential to create local SOPs, use clear severity categories, and keep strong documentation. Aligning internal systems with different regulatory requirements is critical to maintain compliance and protect patient safety.

Reference

• 1. PMDA International Medical Device Regulators Forum (IMDRF)
• 2. China Med Device Emergo by UL
• 3. Canada.ca Emergo by UL
• 4. GOV.UK NSF

Email us at info@sushvin.com | Medical Device Regulatory Updates - Monthly Newsletter | SUSHVIN Consultancy